Salvatore Calabrese - Jul 15, 2022 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Financial Officer
Signature
/s/ Jason Minio, Attorney-in-Fact
Stock symbol
GANX
Transactions as of
Jul 15, 2022
Transactions value $
$0
Form type
4
Date filed
7/19/2022, 04:37 PM
Previous filing
May 23, 2022
Next filing
Mar 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +59.4K $0.00 59.4K Jul 15, 2022 Common Stock 59.4K $4.01 Direct F1
transaction GANX Restricted Stock Units Award $0 +9.9K $0.00 9.9K Jul 15, 2022 Common Stock 9.9K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on July 1, 2023 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F3 The RSUs shall vest 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney